A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lymphoproliferative Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases. The research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions. Another objective is to evaluate the outcomes of patients who are managed with a "watch and wait" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.
Primary outcome measures
- To evaluate 10 year overall survival (OS) of each lymphoproliferative disorder. [Time frame: from 2002 to 2030]
Eligibility criteria
Inclusion criteria
- Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.
- Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document
- Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease
Exclusion criteria
- Patients who are unable to understand informed consent document
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Italy · 1 center
- Fondazione IRCCS Policlinico San Matteo — Pavia
Identifiers
NCT: NCT07519356 · ReLy